Second-generation antipsychotics, also called atypical antipsychotics, are the main class of drugs used to treat schizophrenia. Within this group, risperidone is the most frequently prescribed individual medication, followed by quetiapine and olanzapine. These drugs work by adjusting dopamine and serotonin activity in the brain, which helps reduce hallucinations, delusions, and disordered thinking.
Why Second-Generation Antipsychotics Come First
Treatment guidelines from both the American Psychiatric Association and the UK’s National Institute for Health and Care Excellence recommend second-generation antipsychotics as first-line therapy for schizophrenia. They largely replaced older antipsychotics (like haloperidol) because they carry a lower risk of causing involuntary muscle movements, stiffness, and tremors, side effects that made earlier medications difficult to tolerate long-term.
Prescribing data from first-episode schizophrenia shows how the landscape has shifted. Risperidone accounts for roughly 37% of initial prescriptions, quetiapine about 23%, and olanzapine around 17%. Paliperidone, a closely related medication to risperidone, makes up another sizable share. No single drug is universally “best” for every patient. Doctors typically choose based on a person’s symptom profile, other health conditions, and how they respond to the medication over the first several weeks.
How These Medications Work
Schizophrenia involves overactive dopamine signaling in certain brain pathways. Antipsychotics block dopamine receptors, which dials down the intensity of psychotic symptoms like hearing voices or holding fixed false beliefs. Second-generation antipsychotics also affect serotonin receptors, which is thought to help with mood, motivation, and cognitive symptoms while producing fewer movement-related side effects.
The drugs don’t cure schizophrenia. They manage symptoms, and most people need to take them continuously to stay stable. Stopping medication is one of the most common reasons for relapse.
What the First Weeks of Treatment Look Like
If you or someone you know is starting an antipsychotic, the timeline for improvement follows a fairly consistent pattern. About two-thirds of the improvement seen in the first six weeks actually happens within the first three weeks. By week four, symptom scores typically drop around 20%. A 30% reduction, which represents a meaningful clinical response, often takes the full six weeks or longer.
This matters because early weeks can feel discouraging. Side effects often show up before the full benefit does. Doctors generally recommend staying on a medication for at least four to six weeks at an adequate dose before deciding it isn’t working. Switching too early can mean abandoning a drug that would have helped with more time.
Side Effects to Expect
The trade-off with second-generation antipsychotics is metabolic side effects. These medications can cause weight gain, increased blood sugar, and elevated cholesterol and triglycerides, all of which raise cardiovascular risk over time. The severity varies dramatically between individual drugs.
Olanzapine and clozapine have the worst metabolic profiles. Around six weeks of treatment with either drug can increase body weight by roughly 3 kilograms (about 6.5 pounds) and raise triglyceride levels meaningfully. On the other end of the spectrum, aripiprazole, lurasidone, and ziprasidone have the most favorable metabolic profiles and are often preferred for people already at risk for diabetes or heart disease.
Your doctor will likely monitor your weight, blood sugar, and cholesterol regularly while you’re on these medications. Lifestyle factors like diet and exercise become especially important for people on long-term antipsychotic therapy.
When Standard Medications Don’t Work
About 30% of people with schizophrenia don’t respond adequately to standard antipsychotics. This is called treatment-resistant schizophrenia, and it has its own gold-standard medication: clozapine. Guidelines recommend trying clozapine after at least two different antipsychotics (with at least one being a second-generation drug) have failed at adequate doses.
Clozapine stands apart from other antipsychotics in several ways. In treatment-resistant cases, it produces significant weekly improvement throughout the first six weeks, while other antipsychotics tend to plateau after week three or four. People taking clozapine are 18% less likely to be hospitalized compared to those on standard antipsychotics, with hospitalization rates of about 19% versus 26%. They’re also 27% less likely to stop taking their medication, a strong signal that the drug is working well enough to keep people on it.
The reason clozapine isn’t used first is its side effect profile. Beyond the weight gain and metabolic issues common to its class, clozapine carries a rare but serious risk of reducing white blood cell counts, which can leave the body vulnerable to infections. People taking clozapine need regular blood monitoring, typically weekly at first and then less frequently over time. This requirement creates a barrier to use, but for people who haven’t responded to other treatments, clozapine remains the most effective option available.
Long-Acting Injections as an Alternative
For people who struggle with taking a daily pill, several antipsychotics are available as long-acting injections given every two to four weeks, or in some formulations every few months. Risperidone and paliperidone are among the most commonly used in this form. These injections deliver a steady level of medication and eliminate the daily decision of whether to take a pill, which can be particularly helpful for people whose symptoms include poor insight into their illness.
How the Right Medication Gets Chosen
There’s no blood test or brain scan that predicts which antipsychotic will work best for a given person. The process is largely trial and observation. Doctors weigh several factors: which symptoms are most prominent, whether the person has diabetes or weight concerns that would rule out certain drugs, whether they’ve tried antipsychotics before, and whether a daily pill or monthly injection fits their life better.
If the first medication doesn’t produce enough improvement after an adequate trial of four to six weeks, the typical next step is switching to a different second-generation antipsychotic rather than adding a second drug on top. Only after two adequate trials have failed does clozapine enter the conversation. This stepwise approach balances the need for effective symptom control against the cumulative burden of side effects.